Drug Trial Radar · NCT03863015
IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest
Last checked: Nov 19, 2026Latest source record: Aug 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Mar 4, 2019
Primary completion
Dec 23, 2019
Study completion Jun 30, 2020
Sponsor
- Lead sponsor
- Christian HassagerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Resuscitated cardiac arrest is associated with a systemic inflammatory response that is directly associated with poor prognosis. Inhibition of the IL-6 mediated immune response may potentially inhibit the systemic inflammatory response, potentially improving the prognosis of these severely ill patients.
Conditions
- Heart Arrest
- Out-Of-Hospital Cardiac Arrest
- Systemic Inflammatory Response Syndrome
Interventions
Tocilizumab 20 Mg/mL Intravenous SolutionDrug
Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion
isotonic salineDrug
A one hour infusion of 100mL isotonic saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concentration of hsCRPTime frame: Daily measurements from admission to 72 hours after admission.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.